A useful panel in proliferative urothelial lesions: An analysis of Cytokeratin 20, p53, CD44 and Ki-67 antigens;Panel di ausilio diagnostico nella patologia proliferativa uroteliale: Studio degli Antigeni Citocheratina 20, p53, CD44 e Ki-67

Pathologica

Volumn 99, Issue 2, 2007, Pages 46-49

  Russo, Serena ^a,b,c   Botti, G ^a,b   Vinaccia, P ^a,b   Iaccarino, C ^a,b   Maioli, S ^a,b   Del Prete, D ^a,b   Maiello, F M ^a,b  

^a Ospedale Dei Pellegrini   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NONE   (Italy)

Author keywords

Immunohistochemistry; Neoplasia; Proliferative lesions; Urothelium

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 20; CYTOKERATIN ANTIBODY; HERMES ANTIGEN; KI 67 ANTIGEN; PROTEIN ANTIBODY; PROTEIN P53;

ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; BIOPSY; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ECONOMIC ASPECT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PANEL STUDY; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; UROGENITAL TRACT CANCER; UROGENITAL TRACT DISEASE; UROTHELIUM; CHEMISTRY; PATHOLOGY; URINARY TRACT CANCER;

ANTIGENS, CD44; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; KI-67 ANTIGEN; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 34548396286     PISSN: 00312983     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Epstein JI, Amin MB, Reuter VR, Mostofi FK, and the Bladder Consensus Conference Committee. The World Health Organization/lnternational Society of Urological Pathology Consensus Classification of Urothelial (Transitional cell) Neoplasms of the Urinary Bladder. Am J Surg Pathol 1998;22:1435-48.
2. Epstein JI, Amin MB, Reuter VE. Bladder biopsy interpretation. Lippincott Williams & Wilkins 2004.
3. Limas C, Bair R, Bernhart P, Reddy P. Proliferative activity of normal and neoplastic urothelium and its relation to epidermal growth factor and transferring receptors. J Clin Pathol 1993;46:810-6.
4. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001;165:1124-30.
5. Kirollos MM, McDermott S, Bradbrook RA. Bladder tumor markers: need, nature and application. Nucleus-based markers. Int Urogynecol J Pelvic Floor Dysfunct 1998;9:221-7.
6. McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium. Am J Surg Pathol 2001;25:1074-8.
7. Yin H, Leong A. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. Am J Clin Pathol 2004;121:679-87.
8. Yin H, He Q, Li T, Leong A. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. Appl Immunohistochem Mol Morphol 2006;14:260-5.
9. Mallofre C, Castillo M, Morente V, Sole M. Immunohistochemical expression of CK20, p53 and Ki67 as objective markers of urothelial dysplasia. Mod Pathol 2003; 16:187-91.
10. Kunju LP, Lee CT, Montie J, Shah RB. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Pathol Int 2005;55:248-54.
11. Lopez-Beltran A, Luque R, Moreno A, Bollito E, Carmona E, Montironi R. The pagetoid variant of bladder urothelial carcinoma in situ. Virch Arch 2002;441:148-53.
12. Rey A, Lara PC, Ridondo E, Valdes E, Apolinario R. Ki67 proliferation index in tumors of the upper urinary tract as related to established prognostic factors and long-term survival. Arch Esp Urol 1998;51:204-10.
13. Bol MGW, Baak JPA, van Diermen B, Buhr-Wildhagen, Janssen EAM, Kjellevold KH, et al. Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks. J Clin Pathol 2003;56:447-52.
14. Bol MG, Baak JP, Rep S, Marx WL, Kruse AJ, Bos SD, et al. Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder. J Urol 2003;170:670-1.
15. Moonen L, Ong F, Gallee M, Verheij M, Horenblas S, Hart AA, et al. Apoptosis, proliferation anti p53, cyclin D1 anti retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 2001;49:1305-10.
16. Stavropoulos NE, Filiadis I, Ioachim E, Hastazeris K, Tsimaris I. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer. Anticancer Res 2002;22:3759-64.
17. Rodriguez AA, Pita Fernandez S, Gonzalez-Carrero J, Nogueira March JL. Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67. Actas Urol Esp 2003;27:132-41.